BTIG analyst Dane Leone maintained a Buy rating on MacroGenics (NASDAQ: MGNX) today and set a price target of $30. The company’s shares closed on Friday at $21.51.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 19.9% and a 66.0% success rate. Leone covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics Inc, Blueprint Medicines, and G1 Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MacroGenics with a $34 average price target.
See today’s analyst top recommended stocks >>
Based on MacroGenics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $43.24 million. In comparison, last year the company had a GAAP net loss of $40.65 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its portfolio includes Margetuximab, Flotetuzumab, MGA012, MGD013, Enoblituzumab, MGD009, and Teplizumab.